risk factors for the progression of LUTS from a large scale cohort study with abundant clinical data in Nagahama city, Japan. METHODS: The Nagahama cohort study is a longitudinal and population-based health survey in Nagahama city, Japan and comprised of a questionnaire survey, anthropometric, physiological, and biochemical measures of participants aged 30-75 years. The first sur- vey was performed in 9804 people from 2008 to 2010, and the follow-up evaluation was performed after 5 years as the second survey. We excluded people under 50 years or who did not answer the question- naire completely, resulted in 5284 participants analyzed. International Prostate Symptom Score (IPSS) was used to assess severity of LUTS and causative relationships were evaluated between the progression of LUTS and clinical factors such as BMI, high blood pressure, hyperlip- idemia, renal failure, diabetes, depression and insomnia by multivari- able analyses. RESULTS: The median age of the 5284 participants was 62 years old (50-75, range), men were 1848 individuals (40 %) and median BMI was 22 kg/m2 (14-46). The prevalence of LUTS defined as IPSS over seven was 23 %. As for the proportion of comorbidity, high blood pressure was found in 81 %, hyperlipidemia in 48 %, insomnia in 22 %, depression in 15 %, renal failure in 13 % and diabetes in 6 %. Through 5 years follow-up, total IPSS increased 0.29 points from 5.24 to 5.54 (p<0.0001 by paired t-test). Among each IPSS item, the point of intermittency (0.52 to 0.56, p<0.05 by paired t-test), urgency (0.58 to 0.63, p<0.005), weak stream (0.93 to 1.01, p<0.0001) and nocturia (1.00 to 1.12, p<0.0001) significantly increased while frequency significantly decreased (1.20 to 1.15, p<0.05). Clinical risk factors related to the progression of IPSS were age, male gender, insomnia and depression. Insomnia related to all items of the IPSS progression except frequency. CONCLUSIONS: LUTS, especially intermittency, urgency, weak stream and nocturia, progressed through the 5 years follow-up in the large longitudinal population-based health surveillance. The risk factors for the IPSS progression included age, male gender, depression and insomnia. Insomnia was the most widely associated with the pro- gression of LUTS. Source of Funding: None PD50-09 CHARACTERIZATION OF BLADDER DYSFUNCTION INDUCED BY OVARIECTOMY IN MICE Ei-ichiro Takaoka*, Takahisa Suzuki, Shinsuke Mizoguchi, Jianshu Ni, Pittsburgh, PA; Jun Miyazaki, Chiba, Japan; Hiroyuki Nishiyama, Tsukuba, Japan; Naoki Yoshimura, Pittsburgh, PA INTRODUCTION AND OBJECTIVES: It is well known that postmenopausal estrogen deficiency is associated with lower urinary tract symptoms (LUTS). However, its pathophysiology has not been well clarified partly due to lack of animal studies. In this study, we used mice with ovariectomy (OVX) to evaluate bladder function, molecular changes in bladder mucosa, and the effect of intravesical chemical irritation to elucidate the pathophysiology and therapeutic targets of postmenopausal LUTS. METHODS: In female C57BL/6N mice (8-week-old), OVX was performed via a back incision without touching the urinary bladder (n¼39). Sham operated animals were used as controls (n¼39). Six weeks after the operation, awake cystometrograms (CMG) were recorded in sham and OVX mice. In both groups, intravesical acetic acid (AA) administration was performed with or without intravesical administration of amiloride (an ASIC and ENaC antagonist), and eval- uated the change of CMG parameters after AA stimulation. In addition, the transcript levels of junction molecules (CDH1, Cx43), mechanore- ceptors (TRPV4, ASIC1-3, ENaC a to g), and estrogen receptors (ER a and b) in bladder mucosa were evaluated by RT-PCR. RESULTS: The body weight was significantly increased and the uterus weight was significantly decreased in OVX mice. In CMG, there were no significant differences in CMG parameters at baseline between OVX and sham groups. However, OVX mice showed a significant decrease in intercontraction intervals (ICI) and bladder ca- pacity after intravesical 0.1% AA administration (Figure) whereas 0.1% AA did not affect bladder function in sham mice. Intravesical pre- administration of 1mM amiloride blocked the AA-induced IC reduction in OVX mice (Figure). In RT-PCR, the expression of ASIC1, but not TRPV4, ENaC or others, was significantly increased in bladder mucosa of OVX mice. CONCLUSIONS: OVX mice showed enhanced bladder sensi- tivity dependent on amiloride-sensitive channels, in association with upregulation of ASIC1, a mechano-sensitive channel, in bladder mu- cosa. Thus, it seems likely that estrogen deficiency makes the bladder more susceptible to intravesical stimuli to induce bladder overactivity, which might be a mechanism of storage LUTS in postmenopausal women. Source of Funding: NIH R01DK107450 PD50-10 URINARY MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) EXPRESSION, QUALITY OF LIFE AND SEVERITY OF SYMPTOMS IN PATIENT WITH OVERACTIVE BLADDER (OAB) IN RESPONSE TO SUCCESSFUL TREATMENT Bilal Farhan*, Gamal Ghoniem, Frank Zaldivar, Orange, CA INTRODUCTION AND OBJECTIVES: We hypothesize that MCP-1 urinary levels correlate with OAB patients’ symptom severity. Our aim is to correlate normalized MCP-1 urinary levels to OAB symptoms before and after treatment. We conducted prospective study on patients with OAB symptoms and age-matched controlled. METHODS: Urinary MCP-1 levels were measured in 36 pa- tients with OAB and 13 controls. Patients were treated after the first visit by different OAB treatments (anticholinergic, Beta-3 agonist and or, onabotulinum toxin A, neuromodulations). Urinary MCP-1 levels were measured using enzyme-linked immunosorbent assay (ELISA) and normalized by urinary creatinine levels. The urinary MCP-1 levels and OAB symptoms were compared at baseline, 1 month, and 3 months after treatments. Different validated OAB questionnaires were used. RESULTS: The baseline urinary MCP-1 levels of patients with untreated OAB were significantly higher than that of controls with mean. Patients with OAB had significantly higher baseline urinary MCP-1 levels than that of controls. Urinary MCP-1 levels were significantly reduced at 3 months in 28 OAB-responders (77.8%). On other hand, 8 OAB-non-responders, showed unchanged in urinary MCP-1 (Table 1). The severity of OAB symptoms and QoL had significantly decreased with urinary MCP-1 levels OAB-responders at 1 and 3 months of OAB treatments (Table 2). The OAB symptoms and the quality of life (QoL) of patients significantly changed with the changes in urinary MCP-1 levels of responders at different time points. The severity of OAB symptoms also correlates with the level of MCP-1. Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e973